Skip to content
SZSZSZ985985985

Drawing based on the label description. No photo yet.

“250 mg light brown tablets, debossing: "SZ 985" on one side”

SZ 985 pill

Pill with imprint SZ 985 is brown, octagon, 14 mm and has been identified as Levofloxacin 250 mg. It is used for bronchitis, urinary tract infections (UTIs) and pneumonia. It is supplied by A-S Medication Solutions.

Levofloxacin 250 mg

Imprint
SZ 985
Strength
250 mg
Used for
Bronchitis, urinary tract infections (UTIs) and pneumonia
Color
Brown
Shape
Octagon
Size
14 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
A-S Medication Solutions
Drug class
Antibiotic (fluoroquinolone)
NDC
50090-2001, 0781-5790, 50090-2001-1

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Levofloxacin pills and guides

What is Levofloxacin used for?

Levofloxacin is used for bronchitis, urinary tract infections (UTIs), pneumonia and skin infections.

Medicine type
Antibiotic (fluoroquinolone)
Official uses from the US prescribing label

Nosocomial Pneumonia

Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae,or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosais a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.

Community-Acquired Pneumonia: 7 to 14 day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae(including multi-drug-resistant Streptococcus pneumoniae[MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila,or Mycoplasma pneumoniae.

MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2 ndgeneration cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

Community-Acquired Pneumonia: 5-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae(excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae,or Chlamydophila pneumoniae.

Complicated Skin and Skin Structure Infections

Levofloxacin tablets are indicated in adult patients for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes,or Proteus mirabilis.

Uncomplicated Skin and Skin Structure Infections

Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus,or Streptococcus pyogenes.

Chronic Bacterial Prostatitis

Levofloxacin tablets are indicated in adult patients for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis,or methicillin-susceptible Staphylococcus epidermidis.

Inhalational Anthrax (Post-Exposure)

Levofloxacin tablets are indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracisin adults and pediatric patients, 6 months of age and older. The effectiveness of levofloxacin tablets is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin tablets have not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk.

Plague

Levofloxacin tablets are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis( Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older.

Efficacy studies of levofloxacin tablets could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.

Complicated Urinary Tract Infections: 5-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae,or Proteus mirabilis.

Complicated Urinary Tract Infections: 10-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,or Pseudomonas aeruginosa.

Acute Pyelonephritis: 5 or 10-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.

Uncomplicated Urinary Tract Infections

Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae,or Staphylococcus saprophyticus.

Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin tablets for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options.

Acute Bacterial Exacerbation of Chronic Bronchitis

Levofloxacin tablets are indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae,or Moraxella catarrhalis.

From the FDA-approved label on DailyMed (published Sep 02, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows SZ 985 and the other side has no imprint.
  • It is brown, octagon, 14 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Levofloxacin

Inactive: Silicon Dioxide, Croscarmellose Sodium, Ferric Oxide Yellow, Hydroxypropyl Cellulose, Unspecified, Hypromellose 2910 (15 Mpa.s), Lactose Monohydrate, Polyethylene Glycol 400, Povidone K30, Sodium Starch Glycolate Type A Potato, Talc, Titanium Dioxide, Glyceryl Dibehenate

Other Levofloxacin pills